Bokslutskommuniké for Cline Scientific AB (publ), 556867-8238, for the period 1 January – 31 December 2023
Cline Scientific AB (publ) ("Cline" or the "Company") issues the following bokslutskommuniké for 2023.
July - December 2023
- Net sales amounted to SEK 0 (0).
- Operating profit amounted to SEK 240,145 (237,140).
- Profit per average number of shares after tax amounted to 0.01 (0.01)
January - December 2023
- Net sales amounted to SEK 0 (0).
- Operating profit amounted to SEK -3,108,861 (-2,317,061)
- Profit per average number of shares after tax amounted to -0.10 (-0.15)
The report is published at www.clinescientific.com/financial-reports
For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com
Phone: +46 703-585 088
The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser. The information was submitted for publication via the contact person listed above, at 8.30am CET on 23 February 2024.
Cline Scientific AB (publ)
Pepparedsleden 1
AstraZeneca BioVentureHub Email: info@clinescientific.com
431 53 MÖLNDAL Website: www.clinescientific.com
About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.